Prosecution Insights
Last updated: April 19, 2026

Examiner: ESPINOSA, CLAUDIA EDILMA

Tech Center 1600 • Art Units: 1654

This examiner grants 53% of resolved cases

Performance Statistics

53.3%
Allow Rate
-6.7% vs TC avg
83
Total Applications
+60.0%
Interview Lift
1312
Avg Prosecution Days
Based on 45 resolved cases, 2023–2026

Rejection Statute Breakdown

4.6%
§101 Eligibility
14.1%
§102 Novelty
38.1%
§103 Obviousness
29.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19355164 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS Non-Final OA FILAMON LTD
17556857 PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION Non-Final OA Takeda Pharmaceutical Company Limited
17554539 QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF Non-Final OA Takeda Pharmaceutical Company Limited
17287377 BIOFILM COMPOSITIONS WITH IMPROVED STABILITY FOR NITROGEN FIXING MICROBIAL PRODUCTS Non-Final OA Pivot Bio, Inc.
19204171 CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES Non-Final OA Peptinovo Biopharma Inc.
17413861 LACHNOSPIRACEAE MITIGATES AGAINST RADIATION-INDUCED HEMATOPOIETIC/GASTROINTESTINAL INJURY AND DEATH, AND PROMOTES CANCER CONTROL BY RADIATION Final Rejection The Regents of the University of Michigan
17605283 BONE-SPECIFIC COMPLEX COMPRISING BONE CELL TRANSFORMATION RECOMBINANT PROTEIN AND BONE-TARGETING MOLECULE Final Rejection SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
17762994 HONEY BEE-SAFE ACARICIDAL COMPOUNDS Non-Final OA Board of Regents of The University of Nebraska
17625866 CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATING OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL DISEASE Non-Final OA University of Utah Research Foundation
17594643 METABOLIC ENGINEERING OF NON-PATHOGENIC ESCHERICHIA COLI STRAINS FOR THE CONTROLLED PRODUCTION OF LOW MOLECULAR WEIGHT HEPAROSAN AND SIZE-SPECIFIC HEPAROSAN OLIGOSACCHARIDES Final Rejection University of Utah Research Foundation
18869591 GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS Non-Final OA ARIZONA BOARD OF REGENTS on behalf of the UNIVERSITY OF ARIZONA
18935724 DIETARY EARLY GLYCATION PRODUCTS FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES Non-Final OA University of Georgia Research Foundation, Inc.
17297787 ALKALINE PURIFICATION OF SPIDER SILK PROTEINS Non-Final OA Bolt Threads, Inc.
18162927 METHODS FOR TREATING AMBLYOPIA Non-Final OA City University of Hong Kong
17291290 METHOD FOR PRODUCING TEREPHTHALIC ACID ON AN INDUSTRIAL SCALE Final Rejection CARBIOS
18531687 METHOD OF USING/APPLYING A KERATIN HYDROLYSIS PEPTIDE SOLUTION UPON COFFEE PLANTS TO INCREASE FRUITING YIELD AND WEIGHT Final Rejection CH Biotech R&D Co., Ltd.
17293833 ENGINEERED EXTRACELLULAR VESICLES AND USES THEREOF Non-Final OA LONZA SALES AG
17997376 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS Non-Final OA MEDIMMUNE, LLC
18259040 COMPOUNDS COMPRISING A TETRAPEPTIDIC MOIETY Non-Final OA COBIORES NV
18258577 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALCOHOLIC AND NONALCOHOLIC FATTY LIVER DISEASE Non-Final OA MEDI & GENE
18034718 PEPTIDES AND METHODS OF USE Non-Final OA REALTA LIFE SCIENCES, INC.
17800993 YEAST DISPLAY LIBRARIES, ASSOCIATED COMPOSITIONS, AND ASSOCIATE METHODS OF USE Non-Final OA 3T BIOSCIENCES, INC.
18014321 CD1 PEPTIDE-EPITOPE FOR USE IN THE TREATMENT OF A DISEASE CAUSED BY AN INTRACELLULAR PATHOGEN Non-Final OA IMNATE SARL
17978647 ANTIBIOTIC COMBINATION THERAPIES Final Rejection BIOVERSYS AG
17603750 A METHOD OF PROFILING THE ENERGETIC METABOLISM OF A POPULATION OF CELLS Non-Final OA Université d'Aix Marseille
17595025 VASOACTIVE INTESTINAL PEPTIDE (VIP) FOR USE IN THE TREATMENT OF DRUG-INDUCED PNEUMONITIS Non-Final OA ADVITA LIFESCIENCE GMBH
17406626 METHOD FOR TREATING INFLAMMATORY BOWEL DISEASES Final Rejection NovMetaPharma Co., Ltd.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month